ChitogenX Past Earnings Performance
Past criteria checks 0/6
ChitogenX's earnings have been declining at an average annual rate of -15.3%, while the Biotechs industry saw earnings growing at 13.8% annually.
Key information
-15.3%
Earnings growth rate
1.9%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How ChitogenX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 0 | -3 | 2 | 1 |
| 31 Jul 23 | 0 | -4 | 2 | 2 |
| 30 Apr 23 | 0 | -5 | 3 | 2 |
| 31 Jan 23 | 0 | -6 | 2 | 2 |
| 31 Oct 22 | 0 | -5 | 2 | 2 |
| 31 Jul 22 | 0 | -5 | 2 | 2 |
| 30 Apr 22 | 0 | -5 | 2 | 2 |
| 31 Jan 22 | 0 | -5 | 2 | 2 |
| 31 Oct 21 | 0 | -5 | 2 | 2 |
| 31 Jul 21 | 0 | -4 | 2 | 1 |
| 30 Apr 21 | 0 | -4 | 1 | 1 |
| 31 Jan 21 | 0 | -4 | 1 | 1 |
| 31 Oct 20 | 0 | -3 | 1 | 1 |
| 31 Jul 20 | 0 | -3 | 1 | 1 |
| 30 Apr 20 | 0 | -3 | 1 | 1 |
| 31 Jan 20 | 0 | -2 | 1 | 1 |
| 31 Oct 19 | 0 | -3 | 1 | 1 |
| 31 Jul 19 | 0 | -3 | 1 | 1 |
| 30 Apr 19 | 0 | -3 | 1 | 1 |
| 31 Jan 19 | 0 | -2 | 1 | 1 |
| 31 Oct 18 | 0 | -3 | 1 | 1 |
| 31 Jul 18 | 0 | -2 | 1 | 1 |
| 30 Apr 18 | 0 | -2 | 1 | 1 |
| 31 Jan 18 | 0 | -2 | 1 | 1 |
| 31 Oct 17 | 0 | -1 | 1 | 0 |
| 31 Jul 17 | 0 | -1 | 1 | 0 |
| 30 Apr 17 | 0 | -2 | 1 | 1 |
| 31 Jan 17 | 0 | -2 | 1 | 1 |
| 31 Oct 16 | 0 | -2 | 1 | 1 |
| 31 Jul 16 | 0 | -2 | 1 | 1 |
| 30 Apr 16 | 0 | -1 | 1 | 0 |
Quality Earnings: CHGX is currently unprofitable.
Growing Profit Margin: CHGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CHGX is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.
Accelerating Growth: Unable to compare CHGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CHGX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.